Muscular Dystrophy

All articles by Muscular Dystrophy

FDA approval for Duvyzat builds on Duchenne muscular dystrophy momentum
FDA approval for Duvyzat builds on Duchenne muscular dystrophy momentum
Jack O'Brien
March 22, 2024
12:37 pm

The Duvyzat approval came nine months after the FDA greenlit Sarepta Therapeutics’ Elevidys under the accelerated approval pathway, the first gene therapy to treat DMD.

Muscular Dystrophy Association gears up for Holiday Retail Campaign
Muscular Dystrophy Association gears up for Holiday Retail Campaign
Jack O'Brien
November 2, 2023
4:34 pm

From November to January, MDA is hosting the Holiday Retail Campaign across thousands of retail locations nationwide.

Sarepta’s Duchenne gene therapy fails primary endpoint, but company presses on
Sarepta’s Duchenne gene therapy fails primary endpoint, but company presses on
Lecia Bushak
October 31, 2023
2:46 pm

Sarepta Therapeutics’ Elevidys failed to meet its primary endpoint in a Phase 3 trial, shortly after the FDA granted it accelerated approval for Duchenne muscular dystrophy.

Muscular Dystrophy Association launches 30 Days of Strength campaign
Muscular Dystrophy Association launches 30 Days of Strength campaign
Jack O'Brien
August 28, 2023
11:29 am

MDA stated that its board of directors approved $8.4 million in research grants, which will be distributed next month.

  • From Our Partners